Novo Nordisk
251.85 DKK
+2.32 %
1,012 following
NOVO B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+2.32 %
+1.94 %
-33.42 %
-22.57 %
-30.17 %
-42.22 %
-55.99 %
+14.82 %
+20,128.92 %
Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.
Read moreMarket cap
1.12T DKK
Turnover
1.58B DKK
Revenue
309.06B
EBIT %
41.3 %
P/E
10.92
Dividend yield-%
4.65 %
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
6/5
2026
Interim report Q1'26
5/8
2026
Interim report Q2'26
4/11
2026
Interim report Q3'26
All
Press releases
ShowingAll content types
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
